化学
癌症免疫疗法
免疫疗法
癌症研究
腺苷受体
癌症
腺苷
药理学
受体
生物活性
临床试验
癌细胞
癌症治疗
细胞培养
腺苷A3受体
体外
作者
Yonglian Zhang,Elisabeth T. Hennessy,Matthew A. Larsen,Jingsong Hao,Jianping Pan,Umar Faruk Mansoor,Aaron C. Sather,Zachary G. Brill,Lorena Rico,Uma Swaminathan,Jesus Moreno,Brandon Vara,Sheila H. Ranganath,Anthony Palmieri,Oluwaseun Ogunbodede,Evan R. Barry,Marlene C. Hinton,Pierre Daublain,Pranav Gupta,Manash Shankar Chatterjee
标识
DOI:10.1021/acs.jmedchem.5c03405
摘要
Immune cells expressing the adenosine A 2A receptor (A 2A R) and A 2B receptor (A 2B R) present in an adenosine-rich tumor microenvironment have suppressed effector functions, such as proinflammatory cytokine release, antigen presentation, and others, making them inert to cancer cells. Simultaneous blockade of the downstream effects mediated by both receptor subtypes with a dual inhibitor has the potential to reverse adenosine-mediated suppression of tumor immune surveillance as either a single-agent treatment or in combination with other immunotherapy agents such as anti-PD-1/PD-L1 monoclonal antibodies. This publication describes the discovery and optimization of a novel series of potent and selective dual A 2A R/A 2B R antagonists, resulting in compound 46 ( MK-1088 ) being identified for progression to human clinical studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI